- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
FDA assisted ENDRA Life Sciences in achieving statistical power for a De Novo submission.
1 report, 1 independent
Updated Aug 15
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA assisted ENDRA Life Sciences in achieving statistical power for a De Novo submission.
Who's involved
What this event is mainly aboutKeep exploring
Part of
A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.Also in this story
- A partnership with BARDA has accelerated the development of SCY-247 for the company.
- A company plans to submit regulatory applications to the FDA, EMA, and Australian TGA.
- Approval leads to procurement process initiation.
- UroGen Pharma Ltd., headquartered in Princeton, is seeking FDA approval for its products for the U.S. market.
The entities involved
- FDA
-
ENDRA Life Sciences
Nothing else this week.
Related events
- GSK is submitting data to the FDA regarding potential expansion of its drug indications.
- The FDA requested additional clinical data from Unicycive Therapeutics.
- Emmaus Life Sciences is conducting Phase 3 trials for an Endari drug, preceding future FDA submission.
- Data was presented in Athens supporting a future U.S. NDA submission to the FDA.
- FDA approval is the goal for product candidates from Daré Bioscience, Inc.
Coverage
Newest first; wire copies grouped- Business WireENDRA Life Sciences Provides a Business Update and Reports Second Quarter 2025 Financial Results ANN ARBOR, Mich., August 14, 2025--(BUSINESS WIRE)--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer